The Lung Bacteria Laboratory studies the bacterial pathogens common in cystic fibrosis and related suppurative lung diseases.
Our research focuses on:
- mechanisms of cross-infection
- mechanisms of infection acquisition from the environment and other clinical sources
- determinants of virulence
- persistence and antimicrobial resistance linking genomics with the phenome
- clinical outcomes.
We aim to improve patient outcomes by understanding optimal treatment for chronic infection, and to provide improved diagnostics that result in earlier and more accurate infection-detection.
Group Leader (honorary): Professor Scott Bell
- Dr Laura Sherrard, Visiting Scientist
- Rebecca Stockwell, Research Assistant
- Kay Ramsay, PhD Student (Non-review)
- Michelle Wood, MPhil Student
- Christine Duplancic, Research Officer
- Janine Fenton, Research Assistant
2013 to present
Kidd TJ, Ramsay KA, Hu H, et al. Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres. The European respiratory journal 2013; 41(5): 1091-100.
Plant BJ, Goss CH, Plant WD, Bell SC. Management of comorbidities in older patients with cystic fibrosis. The Lancet Respiratory medicine 2013; 1(2): 164-74.
Ramsay KA, Butler CA, Paynter S, Ware R, Kidd TJ, Wainwright CE, Bell SC. Factors influencing acquisition of Burkholderia cepacia complex in patients with cystic fibrosis. J Clin Micro 2013; 51(12): 3975-80.
Price EP, Sarovich DS, Mayo M, Tuanyok A, Drees KP, Kaestli M, Beckstrom-Sternberg SM, Beckstrom-Sternberg J, Kidd TJ, Bell SC, Keim P, Pearson T, Currie BJ. In vivo evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infection. mBio 2013; 4(4): e00388-13.
Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. The Lancet Respiratory medicine 2014; 2(7): 527-38.
Knibbs LD, Johnson GR, Kidd TJ, et al. Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis. Thorax 2014; 69(8): 740-5.
Smith C, Gras S, Brennan RM, et al. Molecular imprint of exposure to naturally occurring genetic variants of human cytomegalovirus on the T cell repertoire. Scientific reports 2014; 4: 3993.
Smith DJ, Badrick AC, Zakrzewski M, et al. Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. The European respiratory journal 2014; 44(4): 922-30.
Sherrard LJ, Tunney MM, Elborn JS. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet 2014;384(9944):703-13.
Sherrard LJ, Schaible B, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Schneiders T, Elborn JS, Tunney MM. Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients. J Antimicrob Chemother 2014; 69(10):2690-8.
Bell SC, De Boeck K, Amaral MD. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacology & therapeutics 2015; 145: 19-34.
Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. The Medical journal of Australia 2015; 202(3): 130.
Elborn JS, Bell SC, Madge SL, et al. Report of the ERS /ECFS Task force on the care of adults with cystic fibrosis. european Respiratory Journal 2015: in press.
Elborn JS, Geller DE, Conrad D, et al. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of Levofloxacin Inhalation Solution (APT-1026) versus Tobramycin Inhalation Solution in stable cystic fibrosis patients. J Cystic Fibrosis 2015; 14(4): 507-14.
Kidd TJ, Ramsay KA, Vidmar S, et al. Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2015; 14(3): 361-9.
Kidd TJ, Soares Magalhães RJ, Paynter S, Bell SC, Group. TAI. The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa infection: a cross-sectional analysis. Lancet Respiratory Medicine 2015: in press.
Ratjen F, Bell SC, Rowe S, Goss CH, Quittner AL, Bush A. Cystic Fibrosis. Nat Rev Dis Primers 2015: 15010.
Smet B, Mayo M, Peeters C, et al. Burkholderia stagnalis sp. nov. and Burkholderia territorii sp. nov., two novel Burkholderia cepacia complex species from environmental and human sources. International journal of systematic and evolutionary microbiology 2015.
Viberg LT, Price EP, Kidd TJ, Bell SC, Currie BJ, Sarovich DS. Whole-Genome Sequences of Five Burkholderia pseudomallei Isolates from Australian Cystic Fibrosis Patients. Genome announcements 2015; 3(2).
2009 to 2012
Doring, G., P. Flume, H. Heijerman, and J. S. Elborn and the Consensus Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012: 11:461-79.
Kidd TJ, Ritchie SR, Ramsay KA, Grimwood K, Bell SC, Rainey PB. Pseudomonas aeruginosa exhibits frequent recombination, but only a limited association between genotype and ecological setting. PLoS One 2012; 7(9): e44199.
Martin B, Schechter M, Jaffe A, Cooper P, Bell SC, Bye P, Ranganathan S. A comparison of health measures recorded in the United States and Australian Data Registries. Pediatrics. 2012; 129(2): e348-55.
Collaco JM, McGready J, Green DM, Naughton KM, Watson CP, Shields T, Bell SC, Wainwright CE, for the ACFBAL Study Group, Cutting GR. Warmer temperatures are associated with higher prevalence of Pseudomonas aeruginosa and lower lung function in cystic fibrosis. PLoS One 2011; 6(11): e27784.
Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone E, Wainwright C, Konstan M, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS on behalf of the VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D Mutation. NEJM 2011; 365(18): 1663-72.
Bell SC, Bye PTB, Cooper P, Martin AJ, McKay KO, Robinson PJ, Ryan G, Sims G. Cystic Fibrosis in Australia: Results from a Data Registry. MJA 2011; 195: 396-400.
Lewindon PJ, Shepherd RW, Walsh MJ, Greer R, Williamson R, Pereira TN, Frawley K, Bell SC, Smith J, Ramm GA. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53(1): 193-201.
Kidd TJ, Grimwood K, Ramsay KA, Rainey PB, Bell SC. Comparison of three molecular techniques for typing of Pseudomonas aeruginosa isolates in cystic fibrosis sputum. J Clin Micro 2011; 46(1):263-8.
Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes P, King PT, Kolbe J, Landau LI, Maguire G, McDonald M, Reid D, Thien F, Torzillo PJ. Thoracic Society of Australia and New Zealand (TSANZ) and Australian Lung Foundation (ALF) position statement Bronchiectasis and chronic suppurative lung disease in Australia and New Zealand. Medical Journal of Australia 2010; 193(6): 356-65.
Wainwright CE, France MW, O’Rourke P, Anuj S, Kidd TJ, Nissen M, Sloots T, Coulter C, Ristovski Z, Hargreaves M, Rose BR, Harbour C, Bell SC, Fennelly K. Cough-generated Aerosols of Pseudomonas aeruginosa and other Bacteria from Patients with Cystic Fibrosis. (SCB and KF contributed equally to this work). Thorax 2009: 64:926-931.
Vandemheen KL, O’Connor A, Bell SC, Freitag A, Bye P, Jeanneret A, Berthiaume Y, Brown N, Wilcox P, Ryan G, Brager N, Rabin H, Morrison N, Gibson P, Jackson M, Paterson N, Middleton P, Aaron SD. Randomized Controlled Trial Of A Decision Aid For Cystic Fibrosis Patients Considering Referral For Lung Transplantation. Am J Resp Crit Care Med 2009 180: 761-768.
Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cippolli M, Colombo C, Colombo JL, Debray D, Ferdandez A, Lacaiile F, Macek Jr M, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemkova D, Handler AJ, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm M, Wright FA, Lange EM, Durie PR, Knowles MR for the Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009: 302:1076-83.
Downey DG, Bell SC, Elborn JS. Neutrophils in cystic fibrosis (review). Thorax 2009; 64: 81-89.
Manos J, Arthur J, Rose B, Bell S, Webb J, Kjelleberg S, Bye P, Harbour C. Increased expression of attachment, motility and anaerobic respiration genes in clonal Pseudomonas aeruginosa from the CF lung. FEMS Letters 2009; 292: 107-114.
Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD000996.DOI: 10.1002/14651858.CD000996.pub2.
Kidd TJ, Ramsay KA, Hu H, Bye PTP, Elkins MR, Grimwood K, Harbour C, Marks GB, Nissen MD, Robinson PJ, Rose BR, Sloots TP, Wainwright CE, Bell SC and The ACPinCF Investigators. Low rates of Pseudomonas aeruginosa misidentification in cystic fibrosis patients. J Clin Micro 2009: 47: 1503-9.
1996 to 2008
Crough T, Fazou C, Weiss J, Campbell S, Davenport M, Bell SC, Galbraith A, McNeil K, Khanna R. Symptomatic and Asymptomatic Viral Recrudescence in Solid Organ Transplant Recipients and its Relationship with Antigen-Specific CD8+ T-cell Response. J. Virol. 2007; 81: 11538-11542.
McCormack J, Bell SC, Sennini S, Walmsley K, Patel K, Wainwright C, Serisier D, Harris M, Bowler S. Daily versus weekly azithromycin in cystic fibrosis patients. ERJ 2007; 30: 487-495.
Hennig S, Waterhouse TH, Bell SC, France M, Wainwright CE, Miller H, Charles B, Duffull SB. A D-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Brit J Clin Pharm 2007; 63: 438-450.
Hennig S, Wainwright C, Bell SC, Miller H, Friberg L, Charles B. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clinical Pharmacokinetics 2006; 45: 1099-1114.
Block JK, Vandemheen KL, Tullis E, Fergusson D, Dousette S, Hasse D, Berthiaume Y, Brown N, Wilcox P, Bye P, Bell SC, Noseworthy M, Pedder L, Freitag A, Paterson N, Aaron SD. Predictors of serious pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant organisms. Thorax 2006; 61: 969-74.
Buntain HM, Schulter PJ, Bell SC, Greer RM, Wong JCH, Batch J, Lewindon P, Wainwright CE. A longitudinal study of bone mass accrual in Australian children and adolescents with cystic fibrosis. Thorax 2006; 61: 146-154.
Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell SC, Elkins M, Thompson B, MacLeod C, Aaron S, Harbour C. Antibiotic susceptibilities of Pseudomonas aeruginosa derived from patients with cystic fibrosis under aerobic, anaerobic and biofilm conditions. J Clin Micro 2005; 43: 5085-5090.
Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, Berthiaume Y, Brown N, Wilcox P, Bye P, Yozghatlian V, Bell SC, Chan F, Rose B, Jenaeret A, Stevenson A, Noseworthy M, Freitag A, Paterson N, Doucette S, Harbour C, Ruel M, MacDonald N. Multiple combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multi-resistant bacteria. Lancet 2005; 366: 463-471.
O’Carroll MR, Syrmis MW, Wainwright CE, Greer RM, Mitchell P, Nissen MD, Coulter C, Sloots TP, Bell SC. Clonal strains of Pseudomonas aeruginosa shared between paediatric and adult cystic fibrosis centres. Eur Resp J 2004; 24: 101-106.
Buntain HM, Greer RM, Wong JCH, Schulter PJ, Powell E, Potter JM, Batch JA, Lewindon P, Wainwright C, Bell SC. Low bone mineral density in Australian children and adults with cystic fibrosis despite normal vitamin D status. Thorax 2004; 59: 149-155.
O’Carroll MR, Kidd TJ, Smith H, Rose B, Harbour C, Coulter C, Bell SC. Burkholderia pseudomallei: another emerging pathogen in cystic fibrosis? Thorax 2003; 58: 1087-1091.
Skerritt MA, Bharadwaj M, Burrows JM, Morrison L, Davies J, Kear LM, Slaughter R, Bell SC, Galbraith AJ, Khanna R, Moss DJ. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from post-transplant lymphoma after adoptive immunotherapy. Transplantation 2003; 75: 1556-60.
Wolter J, Seeney S, Bell SC, Bowler SD, Masel PJ, McCormack J. Long-term azithromycin therapy improves disease parameters in cystic fibrosis – a randomised control trial. Thorax 2002; 57: 212-216.
Khanna R, Bell SC, Sherritt M, Galbraith AJ, Burrows SR, Rafter L, Clarke B, Slaughter R, Falk MC, Douglass J, Williams T, Elliott SL, Moss DJ. Activation and Adoptive transfer of Epstein-Barr Virus-Specific Cytotoxic T cells in Solid Organ Transplant Patients with Post Transplant Lymphoproliferative Disease. Proc Natl Acad Sci 1999; 96: 10391-10396. (RK and SCB contributed equally to this work).
Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 1998; 157: 1764-1769.
Field PI, Simmel R, Bell SC, Allen DH, Berend N. Evidence for opioid modulation and generation of prostaglandins in SO2-induced bronchoconstruction. Thorax 1996;51: 159-163.
Bell SC, Saunders MJ, Elborn JS, Shale DJ. Resting energy expenditure and oxygen cost of respiration in patients with cystic fibrosis. Thorax 1996;51: 126-131.
Bell SC, Robinson PJ. Prevention of acute exacerbations in cystic fibrosis (review). Thorax 2007; 62: 723-732.
Elborn JS, Bell SC. Editorial. Exacerbations in patients with cystic fibrosis and bronchiectasis. Thorax 2007; 63: 288-290.
Yang IA, Kim ST, Bell SC. Antibiotic therapy for chronic obstructive lung disease, bronchiectasis and cystic fibrosis. In: Evidence-based Respiratory Medicine. Editor: P. Gibson. Blackwell Publishing. 2005.
- Clinical Impact of Clonal Pseudomonas aeruginosa in CF (National study).
- Novel interventions for the diverse population of Australians with bronchiectasis.
- Infectious Aerosol Transport in patients with cystic fibrosis, within hospital and home environments.
- Burkholderia cenocepacia complex infection in patients with cystic fibrosis: whole genome sequencing and correlation with clinical outcomes.
- Elucidating antibiotic resistance mechanisms in chronic Pseudomonas aeruginosa infection
- The emerging problem of non-tuberculous mycobacteria infection: understanding aetiology, geospatial epidemiology and developing interventions
If you wish to apply for QIMR Berghofer's student program,
click here for more information.